Reports Q4 revenue $22.7M, consensus $21.73M. Roderick de Greef, Chairman and CEO, commented, “This past year was a pivotal one for BioLife as we cemented our position as a leading pure play ...

BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and ...

Craig-Hallum analyst Matt Hewitt maintained a Buy rating on BioLife Solutions (BLFS – Research Report) today. The company’s shares closed last Friday at $24.00. See what stocks are receiving ...

CEO Rod de Greef highlighted 2024 as a pivotal year for BioLife, marked by strategic portfolio reshaping, divestitures of non-core product lines, and consistent growth in the Cell Processing platform.

BioLife Solutions Inc (NASDAQ:BLFS) is set to release its Q4 2024 earnings on Mar 3, 2025. The consensus estimate for Q4 2024 revenue is $21.55 million, and the earnings are expected to come in at ...